

# NSCs: Therapeutic Promise and Clinical Challenges

Ashok Menon

Regenerative Neuroscience Lab, BioCell Research University, Chennai, India

## Corresponding Authors\*

Ashok Menon

Regenerative Neuroscience Lab, BioCell Research University, Chennai, India

E-mail: amenon@biocelllab.in

**Copyright:** 2025 Ashok Menon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received:** 01-Oct-2025; **Accepted:** 10-Nov-2025; **Published:** 10-Nov-2025

## Introduction

This article covers the evolving understanding of neural stem cells (NSCs) and their therapeutic potential across various neurological conditions. It highlights recent breakthroughs in NSC transplantation, detailing how these cells can replace damaged neurons, modulate inflammation, and release neurotrophic factors. The authors discuss both successes and ongoing challenges in clinical translation, emphasizing the need for targeted delivery and enhanced survival strategies [1].

This paper dives into the therapeutic applications of neural stem cells (NSCs) specifically for stroke recovery. It elaborates on how NSCs contribute to functional improvement by promoting neurogenesis, angiogenesis, and reducing infarct volume. The authors discuss various delivery methods and strategies to optimize NSC survival and integration, providing a comprehensive overview of preclinical and clinical trial progress while outlining future research avenues [2].

This review focuses on the potential of neural stem cell (NSC) therapy for Parkinson's disease (PD). It explores how NSCs can replace lost dopaminergic neurons, modulate neuroinflammation, and provide neurotrophic support to mitigate PD symptoms. The authors discuss different sources of NSCs, genetic modification strategies to enhance their efficacy, and the challenges of achieving consistent therapeutic outcomes in clinical settings, offering insights into optimizing future trials [3].

This paper examines the role of neural stem cells (NSCs) in treating spinal cord injury (SCI). It details the multi-faceted mechanisms by which NSCs contribute to functional recovery, including remyelination, synapse formation, and the release of factors that reduce secondary injury. The authors review current clinical trials and discuss the critical challenges, such as immune rejection and tumor formation, while suggesting novel strategies to improve therapeutic safety and efficacy [4].

This review provides an updated perspective on neural stem cell (NSC) therapy for Alzheimer's disease (AD). It outlines how NSCs can target multiple pathological hallmarks of AD, including amyloid-beta plaques and tau tangles, through direct replacement, neurotrophic support, and anti-inflammatory effects. The article discusses preclinical models and the transition towards human trials, highlighting the complexities of AD and the need for comprehensive therapeutic approaches involving NSCs [5].

This recent article explores the therapeutic potential of neural stem cells (NSCs) in treating multiple sclerosis (MS). It details how NSCs can promote remyelination, modulate the immune response, and exert neuroprotective effects, addressing both the inflammatory and neurodegenerative aspects of MS. The authors review the latest preclinical and early clinical findings, discussing challenges related to cell delivery, immune rejection, and the complex pathophysiology of MS, while suggesting pathways for future research [6].

This paper focuses on a particularly exciting aspect of neural stem cell (NSC) therapy: the use of exosomes secreted by NSCs. It explains that these extracellular vesicles carry critical therapeutic cargo, including proteins, lipids, and nucleic acids, which can mimic many of the beneficial effects of direct NSC transplantation without the associated risks. The authors discuss the mechanisms of action, potential for targeted delivery, and future prospects of NSC-derived exosomes as a cell-free therapeutic approach for various neurological conditions [7].

This article explores the synergistic potential of combining neural stem cell (NSC) therapy with biomaterials for enhanced brain regeneration. It describes how biomaterial scaffolds can improve NSC survival, differentiation, and integration by providing a supportive microenvironment, guiding cell migration, and delivering essential factors. The authors discuss various biomaterial types, their design considerations, and their application in preclinical models, highlighting how these advanced strategies aim to overcome current limitations of standalone NSC transplantation [8].

This paper reviews the use of induced pluripotent stem cell (iPSC)-derived neural stem cells (NSCs) as a promising source for cell therapy in neurological diseases. It emphasizes the advantages of iPSCs, such as patient-specific derivation and unlimited self-renewal, which address issues of immune rejection and cell availability. The authors discuss the strategies for differentiating iPSCs into specific neural lineages and the challenges associated with ensuring safety and efficacy in clinical applications [9].

This systematic review and meta-analysis critically assesses the safety and efficacy of neural stem cell (NSC) transplantation for various neurological disorders. It synthesizes data from multiple clinical and preclinical studies to provide a comprehensive overview of adverse events and therapeutic benefits. The authors discuss the varying outcomes based on cell source, delivery methods, and patient populations, offering valuable insights into the current state of clinical translation and highlighting areas requiring further investigation to establish standardized protocols [10].

## Description

Neural Stem Cells (NSCs) hold substantial therapeutic promise for a wide array of neurological conditions, representing a pivotal area in regenerative medicine. These cells are known for their inherent capacity to replace damaged neurons, effectively modulate neuroinflammation, and release vital neurotrophic factors. This multifaceted action significantly advances our evolving understanding of neural repair mechanisms and their practical applications [1]. For instance, in the context of stroke recovery, NSCs actively promote neurogenesis, facilitate angiogenesis, and reduce infarct volume, all of which are critical elements contributing to improved functional outcomes following ischemic events [2]. Similarly, for individuals afflicted with Parkinson's disease (PD), NSC therapy is strategically designed to replace lost dopaminergic neurons, diminish debilitating neuroinflammation, and provide essential neurotrophic support, aiming to alleviate the severe motor and non-motor symptoms associated with the condition [3].

Expanding their utility, NSCs are instrumental in facilitating multi-faceted functional recovery in cases of spinal cord injury (SCI). Their contributions involve promoting crucial remyelination, supporting robust synapse formation, and releasing beneficial factors that actively reduce secondary injury cascades, thereby improving recovery prospects [4]. In the ongoing battle against Alzheimer's disease (AD), NSCs are being extensively investigated for their unique ability to target multiple pathological hallmarks, including the infamous amyloid-beta plaques and tau tangles. They achieve this through direct cellular replacement, sustained neurotrophic support, and powerful anti-inflammatory effects, addressing the complex pathology of AD [5]. Furthermore, recent scientific revelations underscore the capacity of NSCs to vigorously promote remyelination, precisely modulate the immune response, and exert broad neuroprotective effects in multiple sclerosis (MS). This comprehensive action tackles both the inflammatory attacks and neurodegenerative progression characteristic of MS [6].

Beyond conventional direct cellular transplantation, the field of NSC therapy is rapidly evolving with several cutting-edge and innovative strategies. A particularly compelling avenue involves the therapeutic application of exosomes secreted by NSCs. These microscopic extracellular vesicles function as sophisticated delivery systems, carrying a rich cargo of critical therapeutic molecules, including proteins, lipids, and various nucleic acids. This cell-free approach can effectively mimic many of the beneficial effects observed with direct NSC transplantation, often without the associated risks of cellular therapies, thus offering a novel and promising therapeutic strategy for diverse neurological disorders [7]. Another significant advancement is the synergistic integration of NSC therapy with advanced biomaterials. These engineered biomaterial scaffolds are meticulously designed to significantly enhance NSC survival rates, guide their precise differentiation into desired cell types, and improve their functional integration within the host tissue. By providing a supportive microenvironment and delivering essential factors, these biomaterial-assisted strategies are proving pivotal in overcoming current limitations of standalone NSC transplantation and maximizing therapeutic efficacy [8].

The origin of NSCs used for therapeutic purposes is a critical factor influencing success and patient compatibility. Induced Pluripotent Stem Cell (iPSC)-derived NSCs represent a revolutionary and highly promising source for cell therapy in neurological diseases. Their primary advantages lie in their patient-specific derivation, which intrinsically minimizes immune rejection, and their virtually unlimited self-renewal capacity, effec-

tively resolving issues related to cell availability for large-scale clinical use [9]. However, the process of differentiating iPSCs into specific functional neural lineages requires meticulous control, and ensuring their safety and long-term efficacy in clinical applications demands rigorous testing and validation. A comprehensive systematic review and meta-analysis plays an indispensable role by critically assessing the overall safety and efficacy of neural stem cell transplantation across various neurological disorders. This type of analysis synthesizes vast amounts of data from numerous clinical and preclinical studies, offering crucial insights into observed adverse events and therapeutic benefits, and highlighting the nuances of clinical translation [10].

Despite the remarkable progress and exciting potential, numerous challenges persist in effectively translating NSC therapies from bench to bedside. These include achieving precise and targeted cell delivery to affected areas, ensuring optimal long-term cell survival and seamless integration within complex neural networks, effectively managing potential immune rejection, and mitigating concerns such as unwanted tumor formation [1, 4]. Current research priorities are sharply focused on optimizing various delivery methods, exploring advanced genetic modification strategies to enhance intrinsic cell efficacy, and developing comprehensive therapeutic approaches that address the multi-factorial nature of neurological diseases [3, 5]. The observed variability in outcomes, often linked to differences in cell source, specific delivery methods, and heterogeneous patient populations, strongly emphasizes the intricate complexity of this field. This underscores the continuous and pressing need for rigorous, further investigation to refine these powerful regenerative strategies and ensure their safe, consistent, and effective delivery to patients who desperately need them [10].

## Conclusion

Neural Stem Cells (NSCs) show immense therapeutic promise across a spectrum of neurological conditions, including stroke, Parkinson's disease, Alzheimer's disease, multiple sclerosis, and spinal cord injury. Research highlights their ability to replace damaged neurons, modulate inflammation, release neurotrophic factors, and promote neurogenesis and angiogenesis. For instance, NSCs contribute to functional recovery in stroke by reducing infarct volume, and they offer neurotrophic support to mitigate Parkinson's disease symptoms. In spinal cord injury, NSCs facilitate remyelination and synapse formation, while in Multiple Sclerosis, they promote remyelination and modulate immune responses. Key strategies to enhance NSC therapy include using biomaterial scaffolds to improve cell survival and integration, and exploring induced Pluripotent Stem Cell (iPSC)-derived NSCs to overcome immune rejection and cell availability issues. A particularly innovative approach involves NSC-derived exosomes, which deliver therapeutic cargo without direct cell transplantation risks. Despite significant breakthroughs, challenges persist in clinical translation, such as targeted delivery, ensuring cell survival, managing immune rejection, and preventing tumor formation. Current research emphasizes optimizing delivery methods, genetic modification strategies, and comprehensive therapeutic approaches. The field is actively investigating the safety and efficacy of NSC transplantation through systematic reviews, aiming to establish standardized protocols and address varying outcomes based on cell source and patient populations. This collective body of work underscores the evolving understanding of NSCs and their multifaceted roles in regeneration and neuroprotection, propelling forward the development of ad-

vanced, safer, and more effective therapies for complex neurological disorders.

## References

1. Yu H, Hongxiang H, Jinming L. Neural Stem Cells in Neurological Diseases: *Recent Advances and Future Perspectives*. *Stem Cell Rev Rep*. 2023;19:1113-1135.
2. Zihan C, Jie Z, Fan F. Neural stem cells for stroke therapy: current progress and future directions. *J Transl Med*. 2022;20:367.
3. Shan G, Yuanyuan Y, Ruichun Z. Advances in Neural Stem Cell Transplantation for Parkinson's Disease. *Front Cell Dev Biol*. 2021;9:728399.
4. Yuting W, Yongwei S, Feng X. Neural stem cell transplantation in spinal cord injury: *Mechanisms and clinical applications*. *Front Cell Neurosci*. 2023;17:1121081.
5. Rong C, Qian QZ, Wen HZ. Neural Stem Cell-Based Therapy for Alzheimer's Disease: *An Updated Review*. *Front Cell Dev Biol*. 2020;8:601339.
6. Ying Z, Mingxia Z, Li S. Neural Stem Cells for the Treatment of Multiple Sclerosis: *Current Research and Future Perspectives*. *Cells*. 2024;13:367.
7. Cheng Z, Qing Y, Yi Y. *Exosomes derived from neural stem cells as a novel therapeutic strategy for neurological disorders*. *Cell Mol Biol Lett*. 2023;28:67.
8. Yu G, Fan L, Jiaheng L. Biomaterial-Assisted Neural Stem Cell Therapy for Brain Regeneration. *Front Cell Dev Biol*. 2022;10:846664.
9. Fang F, Jing Z, Bin C. Induced Pluripotent Stem Cell-Derived Neural Stem Cell Therapy for Neurological Diseases. *Cells*. 2020;9:2470.
10. Jing S, Jian PW, Ying G. Safety and Efficacy of Neural Stem Cell Transplantation for Neurological Disorders: A Systematic Review and Meta-Analysis. *Stem Cells Transl Med*. 2019;8:1146-1159.